|
?:abstract
|
-
Background: Coronavirus disease 2019 (COVID-19) started to spread globally since December 2019 from Wuhan, China Headache has been observed as one of the clinical manifestations in COVID-19 patients We aimed to conduct a comprehensive systematic review and meta-analysis to estimate the overall pooled prevalence of headache in COVID-19 patients Methods: PubMed, Scopus, ScienceDirect, and Google Scholar databases were searched to identify studies published between December 2019 and March 2020 Adult (≥18 years) COVID-19 patients were considered eligible We used random-effects model to estimate the pooled prevalence with 95% confidence intervals (CIs) Quality assessment was done using the Joanna Briggs Institute critical appraisal tools This study is registered with PROSPERO (CRD42020182529) Results: We identified 2,055 studies, of which 86 studies (n = 14,275, 49 4% female) were included in the meta-analysis Overall, the pooled prevalence of headache in COVID-19 patients was 10 1% [95% CI: 8 76-11 49] There was no significant difference of headache prevalence in severe or critical vs non-severe (RR: 1 05, p = 0 78), survived (recovered or discharged) vs non-survived (RR: 1 36, p = 0 23), and ICU vs non-ICU (RR: 1 06, p = 0 87) COVID-19 patients We detected 64 0, 34 9, and 1 1% of the included studies as high, moderate, and low quality, respectively Conclusions: From the first 4-month data of the outbreak, headache was detected in 10 1% of the adult COVID-19 patients
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}